The goal of the Johns Hopkins Brain Cancer Biology and Therapy Laboratory is to locate the genetic and genomic changes that lead to brain cancer. These molecular changes are evaluated for their potential as therapeutic targets and are often mutated genes, or genes that are over-expressed during the development of a brain cancer. The brain cancers that the Riggins Laboratory studies are medulloblastomas and glioblastomas. Medulloblastomas are the most common malignant brain tumor for children and glioblastomas are the most common malignant brain tumor for adults. Both tumors are difficult to treat, and new therapies are urgently needed for these cancers. Our laboratory uses large-scale genomic approaches to locate and analyze the genes that are mutated during brain cancer development. The technologies we now employ are capable of searching nearly all of a cancer genome for molecular alterations that can lead to cancer. The new molecular targets for cancer therapy are first located by large scale gene expression analysis, whole-genome scans for altered gene copy number and high throughput sequence analysis of cancer genomes. The alterations we find are then studied in-depth to determine how they contribute to the development of cancer, whether it is promoting tumor growth, enhancing the ability for the cancer to invade into normal tissue, or preventing the various fail-safe mechanisms programmed into our cells.

The mission of the Lemberg research group is to understand metabolism in childhood/young adult cancers in order to develop a better understanding of how these cancers develop, how they respond to treatments, and how children can go on to live healthy lives with or after a cancer history. We aim to investigate how tumors and the surrounding physiologic environments interact to drive nutrient use so that the tumor can grow and spread, and how the presence of a cancer affects the development of the whole child. Our ultimate goal is to improve outcomes for children and young adults with cancer.

Research in the Lilly Engineer Lab examines the quality and safety of medical care, with a focus on rural and underserved communities. Our current research evaluates methods for improving immunization rates among inner-city populations of school-aged children. We are also exploring the effect of federal policy changes and health care market forces on rural hospitals in the United States.

Lauren Jantzie, professor of pediatrics and vice chair of research for the Department of Pediatrics, received her Ph.D. in neurochemistry from the University of Alberta in 2008. In 2013 she completed her postdoctoral fellowship in the Department of Neurology at Boston Children's Hospital & Harvard Medical School and became faculty at the University of New Mexico. Dr. Jantzie then joined the faculty Departments of Pediatrics (Neonatal-Perinatal Medicine) and Neurology at Johns Hopkins University and the Kennedy Krieger Institute in January 2019.

The Jantzie lab investigates the pathophysiology of encephalopathy of prematurity, and pediatric brain injury common to infants and toddlers. Dr. Jantzie is dedicated to understanding disease processes in the developing brain as a means to identifying new therapeutic strategies and treatment targets for perinatal brain injury. Her lab studies neural substrates of cognition and executive function, inhibitory circuit formation, the role of an abnormal intrauterine environment on brain development, mechanisms of neurorepair and microglial activation and polarization.

Using a diverse array of clinically relevant techniques such as MRI, cognitive assessment, and biomarker discovery, combined with traditional molecular and cellular biology, the Jantzie lab is on the front lines of translational pediatric neuroscience.